Suggested remit: To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating severe chronic rhinosinusitis with nasal polyps.
Status In progress
Decision Selected
Process STA 2018
ID number 3817

Provisional Schedule

Expected publication 20 July 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
14 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
25 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of mepolizumab for treating severe chronic rhinosinusitis with nasal polyps. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
25 January 2021 In progress. Topic is in progress
24 September 2020 - 22 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual